Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease
نویسندگان
چکیده
BACKGROUND Fistulizing Crohn's disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal. Mycobacterium avium ss paratuberculosis (MAP) treatment in CD is gaining attention. AIM We evaluated healing of CD fistula(e) using a novel combination therapy. STUDY Nine consecutive patients who failed to heal fistulae on conventional treatment including anti-TNF, were treated with at least three doses of infliximab, 18-30 courses of hyperbaric oxygen therapy and anti-MAP antibiotics comprising rifabutin, clarithromycin and clofazimine. RESULTS All patients achieved complete healing of fistulae by 6-28 weeks and follow-up for mean 18 months. CONCLUSION Combining infliximab, hyperbaric oxygen therapy and anti-MAP, seems to enable healing of recalcitrant fistulae and although a small case series, all nine patients achieved complete healing.
منابع مشابه
Review article: Medical therapy for fistulizing Crohn's disease.
BACKGROUND Fistulae will develop in approximately one-third of patients with Crohn's disease. With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a medical and possible surgical approach. AIM To summarize the current literature evaluating various medical options for treating patients with fistulizing Crohn's disease. METH...
متن کاملAdalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series
INTRODUCTION Crohn's disease is a chronic inflammatory bowel disease of unknown etiology which may affect any part of the bowel. Fistulas are a common and often serious complication of Crohn's disease. The treatment for fistulizing Crohn's disease can be medical, surgical or a combination of the two. Recently, adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, has been su...
متن کاملPerianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study.
BACKGROUND Perianal fistulizing Crohn's disease is one of the most severe phenotypes of inflammatory bowel diseases. Combined therapy with seton placement and anti-TNF therapy is the most common strategy for this condition. OBJECTIVES The aim of this study was to analyze the rates of complete perianal remission after combined therapy for perianal fistulizing Crohn's disease. METHODS This wa...
متن کاملPredictors of response to infliximab in patients with fistulizing Crohn's disease.
OBJECTIVE To evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. METHODS Consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from base-line in the number of draining fistulae. Complete response was defined as the closure of all fistulae....
متن کاملRetreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
OBJECTIVES Infliximab has clearly demonstrated its efficacy in the short-term treatment of fistulizing Crohn's disease. We present here the results of retreatment and long-term maintenance therapy. PATIENTS AND METHODS Eighty one consecutive patients with active fistulizing Crohn's disease, in whom previous treatments had failed, were treated with infliximab. All patients received as the init...
متن کامل